- Home
- PULM vs CVKD Comparison
PULM vs CVKD Comparison
Compare PULM & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- CVKD
- Stock Information
- Founded
- PULM 2003
- CVKD 2022
- Country
- PULM United States
- CVKD United States
- Employees
- PULM N/A
- CVKD N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- PULM Health Care
- CVKD Health Care
- Exchange
- PULM Nasdaq
- CVKD Nasdaq
- Market Cap
- PULM 21.0M
- CVKD 20.8M
- IPO Year
- PULM N/A
- CVKD 2023
- Fundamental
- Price
- PULM $7.10
- CVKD $19.72
- Analyst Decision
- PULM
- CVKD Strong Buy
- Analyst Count
- PULM 0
- CVKD 1
- Target Price
- PULM N/A
- CVKD $32.00
- AVG Volume (30 Days)
- PULM 37.6K
- CVKD 51.3K
- Earning Date
- PULM 03-27-2025
- CVKD 03-10-2025
- Dividend Yield
- PULM N/A
- CVKD N/A
- EPS Growth
- PULM N/A
- CVKD N/A
- EPS
- PULM N/A
- CVKD N/A
- Revenue
- PULM $10,005,000.00
- CVKD N/A
- Revenue This Year
- PULM N/A
- CVKD N/A
- Revenue Next Year
- PULM $1.00
- CVKD N/A
- P/E Ratio
- PULM N/A
- CVKD N/A
- Revenue Growth
- PULM 47.05
- CVKD N/A
- 52 Week Low
- PULM $1.55
- CVKD $5.40
- 52 Week High
- PULM $8.44
- CVKD $21.30
- Technical
- Relative Strength Index (RSI)
- PULM 62.30
- CVKD 59.55
- Support Level
- PULM $6.84
- CVKD $19.07
- Resistance Level
- PULM $8.14
- CVKD $19.56
- Average True Range (ATR)
- PULM 0.39
- CVKD 1.48
- MACD
- PULM 0.11
- CVKD 0.01
- Stochastic Oscillator
- PULM 71.43
- CVKD 69.69
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.